TSMHT
INMB icon

Thurston Springer Miller Herd & Titak’s INmune Bio INMB Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-106
Closed -$244 – 950
2025
Q2 		$244 Buy
106
+28
+36% +$205 ﹤0.01% 1589
2025
Q1 		$609 Hold
78
– – ﹤0.01% 1567
2024
Q4 		$364 Buy
+78
New +$407 ﹤0.01% 1272

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's INMB Position: Q3 2025 in Review

Thurston Springer Miller Herd & Titak sold out of INmune Bio (INMB) in Q3 2025, closing a stake of 106 shares — an estimated $244 sold.

Thurston Springer Miller Herd & Titak first reported a position in INMB in Q4 2024 and held it in 3 quarters. The position peaked at $609 in Q1 2025. 73 funds tracked by Wall St. Rank hold INMB as of Q3 2025.

  • Thurston Springer Miller Herd & Titak reported no remaining INmune Bio position as of Q3 2025 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 106 INmune Bio shares in Q3 2025, an estimated $244.
  • Thurston Springer Miller Herd & Titak first reported a position in INmune Bio in Q4 2024 and held it in 3 quarters.
  • Thurston Springer Miller Herd & Titak's INmune Bio position peaked at $609 in Q1 2025.
  • 73 funds tracked by Wall St. Rank held INmune Bio as of Q3 2025.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2025, filed 7 Oct 2025.